← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Inimmune Corporation
Missoula, MT
$12,164,037
Total funding
7
Grants
Funding over time
peak $2.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,164,037 · 7
By mechanism
N01$7,140,989 · 3
N44$3,828,924 · 2
R44$1,017,317 · 1
R43$176,807 · 1
Investigators at Inimmune Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES$2,515,245
N01 · FY2024 · AI
Production of Synthetic Adjuvant System (SAS)$1,992,471
N44 · FY2020 · AI
Development of a new TLR4 agonist for the treatment of Allergic Rhinitis$1,836,453
N44 · FY2021 · AI
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES$1,744,408
N01 · FY2023 · AI
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES$1,648,211
N01 · FY2025 · AI
Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model$598,808
N01 · FY2021 · AI
Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis$592,624
N01 · FY2018 · AI
Novel synthetic TLR4 agonists$580,244
R44 · FY2020 · AI
Novel synthetic TLR4 agonists$437,073
R44 · FY2019 · AI
Novel synthetic TLR4 agonists$176,807
R43 · FY2018 · AI
Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis$41,693
N43 · FY2019 · AI